Stemedica

Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing progenitor cell and protein therapies for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform to produce allogeneic progenitor cell products with intellectual property protection in a cGMP-compliant manufacturing facility under low oxygen and low tension environments. The company’s lead product candidate, ischemia-tolerant mesenchymal stem cells (itMSCs), is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second product candidate, ischemia-tolerant neural stem cells (itNSCs), is an allogeneic cell therapy currently being developed for spinal cord injury.